Neurodegenerative and cerebrovascular disorders are among the most common neurological diseases. Significant progress has been made toward gaining insights into the causes of many of these prevalent illnesses, but the nature of the mechanisms by which neurons die under these pathological conditions remains poorly understood. In search of such molecular clues, many scientists now believe that abnormal kinase signaling, especially involving the proline-directed serine/threonine protein kinase, cyclin-dependent kinase 5 (Cdk5), might be an important piece of the puzzle.
Cdk5 is ubiquitously expressed in neurons, but the associated kinase activity is tightly controlled by its major non-cyclin activator p35 (Dhavan and Tsai, 2001) . Several lines of evidence indicate that Cdk5 contributes to normal brain development where it plays a role in axon guidance and neuronal migration (Dhavan and Tsai, 2001) . Cdk5, through the phosphorylation of a broad range of pre-and postsynaptic proteins, also regulates neurotransmission and synaptic plasticity, and thus, plays an important role in cognitive functions such as learning and memory (Cheung et al., 2006; Fischer et al., 2005) . Cdk5 may also modulate locomotor responses to cocaine (Meyer et al., 2008) . The above examples illustrate the broad range of Cdk5 functions in the nervous system. Furthermore, aberrant Cdk5 signaling has been proposed to be a common contributor to a variety of CNS disorders (Cruz and Tsai, 2004; Nguyen et al., 2003; Qu et al., 2007; Rashidian et al., 2005) . Cdk5 deregulation is presumably the consequence of a neuronal accumulation of p25, a C-terminal fragment of p35 generated by the Ca 2+ -dependent proteases calpains (Lee et al., 2000) . While p25 encompasses the minimal region required for Cdk5 binding and activation, it lacks the p35 N-terminal myristoylation signal and, unlike p35, it is not readily degraded by the proteasome system (Dhavan and Tsai, 2001 ). Consequently, p25/Cdk5 complex is not properly targeted to the plasma membrane and Cdk5 is hyperactivated.
To determine whether the generation and accumulation of p25 followed by alterations in Cdk5 signaling can indeed cause neuronal death, bitransgenic mice were created to have an inducible expression of GFP-tagged human p25 in forebrain neurons (Cruz et al., 2003) . Research on these mice has been quite enlightening in that, upon postnatal doxycycline withdrawal, not only do these animals show high forebrain p25 levels and Cdk5 activity, they also develop cognitive deficits, brain atrophy, and overt hippocampal neuronal loss and gliosis (Cruz et al., 2003; Fischer et al., 2005) . However, these studies have not shed light on the precise molecular mechanisms by which p25/Cdk5 mediate neuronal death. In this issue of Neuron, Kim and collaborators ) identify a novel and exciting mechanistic link between aberrant p25/Cdk5 signaling, histone deacetylases (HDACs), and neurodegeneration.
Kim and colleagues began their search for the missing link between p25/Cdk5 and neuronal death by screening for early transcriptional differences in adult p25 induced transgenic mice and noninduced controls. By microarray profiling, Kim et al. found that 1/3 of the differentially regulated genes encoded for either cell cycle factors or DNA damage/repair response proteins. The authors hypothesized that an increase in histone acetylation due to reduced HDAC activity, through its effects on chromatin remodeling and transcriptional regulation, may well be the culprit. Among the large number of HDAC isoforms, Kim et al. likely focused on HDAC1, because its inhibition is associated with transcriptional alterations (Peart et al., 2005) and because HDAC1 plays an essential and nonredundant role in development and cell survival (Lagger et al., 2002) .
Previous studies have found that many molecules that interact with Cdk5 also bind to p35 and p25. The authors found that a region in the N-terminal region of HDAC1, within its histone deacetylase catalytic domain, bound directly to p25 and that this interaction impaired HDAC1 functions. Inactivation of HDAC1 led to an aberrant expression of cell cycle proteins and an accumulation of DNA damage, ultimately provoking cell death via apoptosis, similar to the pathology seen after transient cerebral ischemic events. Strikingly, the authors found that somatic overexpression of wild-type HDAC1 attenuated this ischemic-related pathologic phenotype.
While these results support the potential benefit of promoting HDAC1 activity to fight against ischemic-related neurodegeneration, further studies will be needed to decipher the precise nature of this Cdk5-dependent effect on HDAC1. From a preclinical standpoint, additional insight could have been gained if the authors had assessed the effects of targeting HDAC1 activity, not only before, but also after the ischemic accident, to better emulate the situation encountered in patients. Nonetheless, the results are an important starting point for future studies. In contrast to the data presented here, preclinical studies using either pan-or class-specific-HDAC antagonists have shown that inhibition, and not stimulation of protein deacetylation, was protective against neurodegeneration in models of motor neuron or polyglutaminerepeat diseases (Kazantsev and Thompson, 2008) . Could these contradicting results reflect disease pathways involving specifically different HDAC isoforms? Interestingly, the HDAC1 binding domain with p25 share 90% sequence homology with HDAC2 and 50% with HDAC3. Thus, it may also be informative to know whether p25 binds to and affects the activity of these distinct class-I HDAC isoforms, particularly since they may have different binding partners and functions in unique subcellular compartments (Kazantsev and Thompson, 2008) .
Kim and collaborators provide a tantalizing new scenario for p25/Cdk5-mediated neurodegeneration articulated around HDAC1 inactivation and an ensuing inappropriate reactivation of the cell cycle and an accumulation of DNA damage, but several additional p25/Cdk5-related pathogenic scenarios have been characterized (Figure 1 ). For instance, it has also been proposed that p25/Cdk5 deleterious effects could result from the hyperphosphorylation of tau and other neuronal substrates (Cruz and Tsai, 2004; Nguyen et al., 2003) , increased NMDA receptor channel activity (Wang et al., 2003) , inhibition of peroxiredoxin-2 (Qu et al., 2007) , or even induction of b-secretase (Wen et al., 2008) . Since these observations were made in different disease models, it is possible that p25/Cdk5 recruits distinct deleterious cascades, depending on the initiating event (e.g., ischemia versus neurotoxin) or the type of neurons affected (e.g., cholinergic versus dopaminergic).
Alternatively, these mechanisms are not necessarily mutually exclusive and therefore, the most parsimonious explanation would be to consider that most, if not all, of these mechanisms may be effectors of aberrant p25/Cdk5 activation and contribute to the neurodegenerative process. If correct, this view will have far-reaching implications to both our understanding of the function of p25/Cdk5 and the neurobiology of a range of disease mechanisms. Indeed, this work firmly places p25/Cdk5 at the crossroads toward which many disease-initiating factors converge and from which many cell death effectors depart.
